Lubiprostone for Chronic Idiopathic Constipation Treatment

Summary

The purpose of this study is to evaluate the efficacy and safety of oral administration of 24 ug of lubiprostone twice daily (BID) for 4 weeks in participants with chronic idiopathic constipation (CIC) compared with placebo.

Timeline

Start

2016-05-11

Primary completion

2017-04-28

Completion

2017-06-05

Outcome

Met primary endpoint

registry analysis (superiority test); Lubiprostone 24 μg vs Placebo; p = 0.020; Median Value of confidence interval (CI) 1.0 (95% CI 0.1 to 1.9); Van Elteren Test NCT02729909 ↗

Drugs

Indications